Cargando…
The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
BACKGROUND: Shared decision-making in rheumatoid arthritis (RA) care is a priority among policy makers, clinicians and patients both nationally and internationally. Demands on patients to have basic knowledge of RA, treatment options, and details of risk and benefit when making medication decisions...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363399/ https://www.ncbi.nlm.nih.gov/pubmed/25649726 http://dx.doi.org/10.1186/s12911-014-0104-8 |
_version_ | 1782361907562283008 |
---|---|
author | Barton, Jennifer L Koenig, Christopher J Evans-Young, Gina Trupin, Laura Anderson, Jennie Ragouzeos, Dana Breslin, Maggie Morse, Timothy Schillinger, Dean Montori, Victor M Yelin, Edward H |
author_facet | Barton, Jennifer L Koenig, Christopher J Evans-Young, Gina Trupin, Laura Anderson, Jennie Ragouzeos, Dana Breslin, Maggie Morse, Timothy Schillinger, Dean Montori, Victor M Yelin, Edward H |
author_sort | Barton, Jennifer L |
collection | PubMed |
description | BACKGROUND: Shared decision-making in rheumatoid arthritis (RA) care is a priority among policy makers, clinicians and patients both nationally and internationally. Demands on patients to have basic knowledge of RA, treatment options, and details of risk and benefit when making medication decisions with clinicians can be overwhelming, especially for those with limited literacy or limited English language proficiency. The objective of this study is to describe the development of a medication choice decision aid for patients with rheumatoid arthritis (RA) in three languages using low literacy principles. METHODS: Based on the development of a diabetes decision aid, the RA decision aid (RA Choice) was developed through a collaborative process involving patients, clinicians, designers, decision-aid and health literacy experts. A combination of evidence synthesis and direct observation of clinician-patient interactions generated content and guided an iterative process of prototype development. RESULTS: Three iterations of RA Choice were developed and field-tested before completion. The final tool organized data using icons and plain language for 12 RA medications across 5 issues: frequency of administration, time to onset, cost, side effects, and special considerations. The tool successfully created a conversation between clinician and patient, and garnered high acceptability from clinicians. CONCLUSIONS: The process of collaboratively developing an RA decision aid designed to promote shared decision making resulted in a graphically-enhanced, low literacy tool. The use of RA Choice in the clinical encounter has the potential to enhance communication for RA patients, including those with limited health literacy and limited English language proficiency. |
format | Online Article Text |
id | pubmed-4363399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43633992015-03-19 The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter Barton, Jennifer L Koenig, Christopher J Evans-Young, Gina Trupin, Laura Anderson, Jennie Ragouzeos, Dana Breslin, Maggie Morse, Timothy Schillinger, Dean Montori, Victor M Yelin, Edward H BMC Med Inform Decis Mak Research Article BACKGROUND: Shared decision-making in rheumatoid arthritis (RA) care is a priority among policy makers, clinicians and patients both nationally and internationally. Demands on patients to have basic knowledge of RA, treatment options, and details of risk and benefit when making medication decisions with clinicians can be overwhelming, especially for those with limited literacy or limited English language proficiency. The objective of this study is to describe the development of a medication choice decision aid for patients with rheumatoid arthritis (RA) in three languages using low literacy principles. METHODS: Based on the development of a diabetes decision aid, the RA decision aid (RA Choice) was developed through a collaborative process involving patients, clinicians, designers, decision-aid and health literacy experts. A combination of evidence synthesis and direct observation of clinician-patient interactions generated content and guided an iterative process of prototype development. RESULTS: Three iterations of RA Choice were developed and field-tested before completion. The final tool organized data using icons and plain language for 12 RA medications across 5 issues: frequency of administration, time to onset, cost, side effects, and special considerations. The tool successfully created a conversation between clinician and patient, and garnered high acceptability from clinicians. CONCLUSIONS: The process of collaboratively developing an RA decision aid designed to promote shared decision making resulted in a graphically-enhanced, low literacy tool. The use of RA Choice in the clinical encounter has the potential to enhance communication for RA patients, including those with limited health literacy and limited English language proficiency. BioMed Central 2014-11-25 /pmc/articles/PMC4363399/ /pubmed/25649726 http://dx.doi.org/10.1186/s12911-014-0104-8 Text en © Barton et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Barton, Jennifer L Koenig, Christopher J Evans-Young, Gina Trupin, Laura Anderson, Jennie Ragouzeos, Dana Breslin, Maggie Morse, Timothy Schillinger, Dean Montori, Victor M Yelin, Edward H The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter |
title | The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter |
title_full | The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter |
title_fullStr | The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter |
title_full_unstemmed | The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter |
title_short | The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter |
title_sort | design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363399/ https://www.ncbi.nlm.nih.gov/pubmed/25649726 http://dx.doi.org/10.1186/s12911-014-0104-8 |
work_keys_str_mv | AT bartonjenniferl thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT koenigchristopherj thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT evansyounggina thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT trupinlaura thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT andersonjennie thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT ragouzeosdana thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT breslinmaggie thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT morsetimothy thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT schillingerdean thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT montorivictorm thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT yelinedwardh thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT bartonjenniferl designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT koenigchristopherj designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT evansyounggina designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT trupinlaura designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT andersonjennie designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT ragouzeosdana designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT breslinmaggie designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT morsetimothy designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT schillingerdean designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT montorivictorm designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter AT yelinedwardh designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter |